Effect of Licorice-Based LDD Membrane With or Without Oral Supplementation on HMGB1 Levels in GCF and Peri-Implant Marginal Bone in Type 2 Diabetic Patients: A Randomized Controlled Trial

INTERVENTION: Intervention1: Glycyrrhiza Glabra (licorice) incorporated bioactive membrane for local drug delivery with Implant placement: 16microgram/ml Control Intervention1: Glycyrrhiza Glabra (licorice) incorporated bioactive membrane for local drug delivery with oral supplementation with Implant Placement: 750mg of licorice for 4 weeks with regular monitoring of glucose levels Control Intervention2: Only implant placement: NIL CONDITION: Health Condition 1: E119‐ Type 2 diabetes mellitus without complications PRIMARY OUTCOME: HMGB1 levels in GCF using ELISA will be assessed at baseline ad 3 months ; Marginal Bone Levels using grid by paralleling technique by IOPA at baseline, 3 months and 6 monthsTimepoint: HMGB1 levels in GCF using ELISA will be assessed at baseline and 3 months ; Marginal Bone Levels using grid by paralleling technique by IOPA at baseline, 3 months and 6 months SECONDARY OUTCOME: Gingival index, Plaque index, Pocket probing depth, Fasting blood sugarTimepoint: baseline,3months,6months INCLUSION CRITERIA: Patients diagnosed with controlled Type 2 Diabetes Mellitus (HbA1c 6.1‐8%)19 Patients aged between 20 years and 0 days 65 years and 0 days Patients requiring delayed implant placement Patients having adequate bone volume for implant placement Patients willing to participate and sign informed consent